Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …

Background Gastric cancer is the most common cancer and the fourth most common cause
of cancer death in South Korea [1]. Despite the large number of gastric cancer patients …

Background KEYNOTE‐063 (NCT03019588) investigated pembrolizumab versus paclitaxel
as second‐line therapy in Asian patients with advanced programmed death ligand 1 (PD …

Countries differ in their treatment expertise and research results regarding gastric cancer;
hence, treatment guidelines are diverse based on evidence and medical situations. A …

Gastric cancer is one of the most common cancers in both Korea and worldwide. Since
2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with …

Gastric cancer (GC) is a molecularly heterogeneous disease. Its molecular background,
epidemiology, and standard of care are quite different between Eastern and Western …

Gastric cancers are highly prevalent in both the East and the West, although they differ in
aetiology and prognostic outcome. Management of gastric cancer from screening to …

Background Both apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb)
monotherapy have been licensed in China for the third-line treatment of advanced gastric …

Background Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ)
is an aggressive disease with poor prognosis. In the TAGS study, trifluridine/tipiracil …

Importance Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with
pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC) …